Anemia D000740

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia

Description

A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.   MeSH

Subtype Terms (9)

Anemia, Aplastic
94 drugs (56 approved, 38 experimental)

Anemia, Hemolytic
17 drugs (16 approved, 1 experimental)

Anemia, Hypochromic
2 drugs (1 approved, 1 experimental)

Anemia, Macrocytic
 

Anemia, Myelophthisic
 

Anemia, Neonatal
5 drugs (1 approved, 4 experimental)

Anemia, Refractory
62 drugs (36 approved, 26 experimental)

Anemia, Sideroblastic
 

Red-Cell Aplasia, Pure
18 drugs (15 approved, 3 experimental)



Organization Involved with Phase 4 Indications (163)

Organization Involved with Phase 3 Indications (181)

Organization Involved with Phase 2 Indications (131)

Organization Involved with Other Experimental Indications (75)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.